Friday, August 24, 2012

Iatrogenic prion diseases in humans: an update

Iatrogenic prion diseases in humans: an update

Gorka Barrenetxea Affiliations Tel.: +34 4396062; fax: +34 4395424. Quiron Bilbao, Assisted Reproduction Center, Universidad del PaĆ­s Vasco/Euskal Herriko Unibertsitatea, Ribera Botica Vieja 23, 48014 Bilbao, Spain

Received 8 January 2012; received in revised form 2 July 2012; accepted 8 August 2012. published online 24 August 2012. Uncorrected Proof


Although Creutzfeldt–Jakob disease (CJD) was first identified in 1920, prevention of transmission raised particular concern all over the world when a new variant of the disease was first described in 1996. There is good evidence of iatrogenic transmission of this new variant among human beings through blood, blood components, tissues and growth hormone. Furthermore, four cases of iatrogenic transmission of CJD through fertility treatment with human pituitary-derived gonadotrophins have been reported.

It is important to distinguish the categories of infectivity and categories of risk, which require consideration not only of the level of infectivity of a given tissue or fluid, but also the amount of tissue/fluid to which a person is exposed, the duration of exposure and the route by which infection is transmitted.

The potential presence and infectivity of prion proteins in human urinary gonadotrophin preparations is a matter of debate. Differences in the sensitivity of bioassay methods are of paramount importance when considering the infectivity of a tissue. Some new methods might detect small amounts of agent in some tissues currently thought to be free of infectivity.

No cases of human prion disease due to the use of urinary gonadotrophins have been recognized to date. However, the detection of prions in the urine of experimental animals and in some urine-based preparations, and the young age of fertility drug recipients, require the application of the precautionary principle to urinary preparations.

Keywords: Prion diseases, Urine-derived gonadotrophins, Transmissible spongiform encephalopathy, Iatrogenic Creutzfeldt–Jakob disease, Prionuria, Tissue infectivity

Friday, March 25, 2011

Detection of Prion Protein in Urine-Derived Injectable Fertility Products by a Targeted Proteomic Approach

Friday, August 10, 2012

Incidents of Potential iatrogenic Creutzfeldt-Jakob disease (CJD) biannual update (July 2012)

North America has NO surveillance system for iatrogenic CJD. a few mishaps of late ;

Tuesday, July 31, 2012

11 patients may have been exposed to fatal disease Creutzfeldt-Jakob Disease CJD Greenville Memorial Hospital

Thursday, August 02, 2012

CJD case in Saint John prompts letter to patients Canada CJD case in Saint John prompts letter to patients

Friday, June 29, 2012

Highly Efficient Prion Transmission by Blood Transfusion

Sunday, June 3, 2012

A new neurological disease in primates inoculated with prion-infected blood or blood components

Thursday, August 16, 2012

Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease ( vCJD) USA JUNE, JULY, AUGUST 2012

Wednesday, May 16, 2012

Alzheimer’s disease and Transmissible Spongiform Encephalopathy prion disease, Iatrogenic, what if ?

Proposal ID: 29403

Monday, August 13, 2012

Summary results of the second national survey of abnormal prion prevalence in archived appendix specimens August 2012

RedCross Request Jerome H. Holland Laboratory is collecting small volumes of blood from patients afflicted with various forms of transmissible spongiform encephalopathies (TSE)/prion diseases and their blood-related family members 2012



The American National Red Cross (Red Cross) Jerome H. Holland Laboratory for Biomedical Research in Rockville, Maryland is collecting small volumes of blood from patients afflicted with various forms of transmissible spongiform encephalopathies (TSE)/prion diseases and their blood-related family members. The purpose of the research is to build a blood sample repository for studies on ways to detect the presence of prion protein or other markers of the disease in human blood.

Recent epidemiological evidence indicates that blood of patients with variant form of Creutzfeldt-Jakob disease (vCJD), that is prevalent in the United Kingdom, is infectious.

The questions about the possibility that blood from patients with the sporadic and familial forms of TSE might also be infectious is still not resolved even though 10 years of searching has not revealed any examples of blood-related transmission from patients with these non-variant forms of disease.

The development of a blood test to identify affected people in the pre-clinical stage of disease could eliminate the uncertainty about TSE-related blood safety. Some tests have been successful for testing animals infected with TSEs, but in order to know if any test will be reliable in humans, we need to test human blood.

CJD patients and their families are the only source of blood specimens that can answer this question, and we therefore ask you to support our effort.

If you or an affected relative is interested in participating, please contact the name listed below. No more than 50 ml of blood should be collected at a location convenient to you through your own arrangements with your physician and the blood sample should be sent to the Holland Laboratory at no cost to you. The samples will be processed and stored, frozen indefinitely, at the Holland Laboratory in Rockville, Maryland. The Red Cross will provide access to only designated research staff at the Red Cross or other research groups that have provided convincing evidence for a test to detect TSE in animals.

Participating individuals will NOT be notified about test results because the tests that will be performed on blood are experimental and their significance is not known and will remain uncertain for some years to come. The CJD foundation will be notified of any publications coming from our research.

Contact information:

Dr. Larisa Cervenakova; Phone: 301-738-0765; e-mail:

Dr. Larisa Cervenakova

Senior Scientist, Biomedical Services

American Red Cross

15601 Crabbs Branch Way

Rockville, MD 20855

(240) 314-3536 (p)

(240) 888-3615 (c)

(301) 610-4120 (f)

Coordinator for the CJD Lookback Study. The study is ongoing and we are looking for blood donors who subsequently develop CJD.

Below is my contact information, please feel free to pass on my information to those family members who want to participate in the Lookback Study.

Kerri Dorsey, MPH

Project Manager 1

American Red Cross

Holland Laboratory

Transmissible Disease Department

15601 Crabbs Branch Way

Rockville, MD 20855

Ph: 240-314-3523

Fax: 301-610-4121




Thursday, June 2, 1999

CHAIRMAN BROWN: My name is Dr. Paul Brown. Welcome to the FDA traveling road show. We are asked yet once more by the FDA to consider a question of theoretical risk in the absence of sufficient knowledge on which to base any firm conclusion. The issue before us today is that of excluding categories of American blood donors who have either visited or resided for longer periods of time in Great Britain. The issue is sufficiently delicate, as you see that we have been moved outside the Beltway. (Laughter.)snip... "Dr. Alan Williams is employed by the American Red Cross, Holland Labs,and is Scientific Adviser for the Florida Blood Services and Canadian Blood Services. In addition, he has financial interests in firms that could be affected by the general discussions. "Dr. Richard Race has financial interests in firms that could be affected by the general discussions and is a public health science researcher. "In the event that the discussions involve specific products or specific firms for which FDA participants have a financial interest, the participants are aware of the need to exclude themselves from such involvement. And their exclusion will be noted for the public record. A copy of the waivers is available by written request under the Freedom of Information Act. "With respect to all other meeting participants, we ask in the interest of fairness that they address any current or previous financial involvement with any firm whose product they may wish to comment upon." So ends the reading of the conflict of interest statement. Dr. Brown, I turn the meeting over to you.snip...

Saturday, May 26, 2012

Are USDA assurances on mad cow case 'gross oversimplification'?


What irks many scientists is the USDA’s April 25 statement that the rare disease is “not generally associated with an animal consuming infected feed.”

The USDA’s conclusion is a “gross oversimplification,” said Dr. Paul Brown, one of the world’s experts on this type of disease who retired recently from the National Institutes of Health. "(The agency) has no foundation on which to base that statement.”

“We can’t say it’s not feed related,” agreed Dr. Linda Detwiler, an official with the USDA during the Clinton Administration now at Mississippi State.

In the May 1 email to me, USDA’s Cole backed off a bit. “No one knows the origins of atypical cases of BSE,” she said

The argument about feed is critical because if feed is the cause, not a spontaneous mutation, the California cow could be part of a larger outbreak.



Saturday, August 4, 2012

Final Feed Investigation Summary - California BSE Case - July 2012



Summary Report BSE 2012

Executive Summary

Saturday, August 4, 2012

Update from APHIS Regarding Release of the Final Report on the BSE Epidemiological Investigation

in the url that follows, I have posted

SRM breaches first, as late as 2011.


MAD COW FEED BAN BREACHES AND TONNAGES OF MAD COW FEED IN COMMERCE up until 2007, when they ceased posting them.



Friday, May 18, 2012

Update from APHIS Regarding a Detection of Bovine Spongiform Encephalopathy (BSE) in the United States Friday May 18, 2012

Monday, August 6, 2012

TAFS BSE in USA August 6, 2012


Monday, July 23, 2012

The National Prion Disease Pathology Surveillance Center July 2012


No comments:

Post a Comment